The emerging role of nimotuzumab in the treatment of non-small cell lung cancer

Figures & data

Table 1 Trials of nimotuzumab in solid tumors (excluding NSCLC)

Authors	Phase	Location	No. of patients	Cancer stages	ORR	DCR	MST(mo)	vs controls
Crombet et al^Citation37 (2003)	I	Cuba	12	Advanced epithelial
Winquist et al^Citation46 (2002)	I	Canada	17	HNSCC	87.5%
Crombet et al^Citation70 (2004)	I/II	Cuba	22	HNSCC	88%@200 or 400 mg		8.6@50 and 100 mg; 44.3@200 and 400 mg
Rojo et al^Citation47 (2008)	I	Spain	10	Advanced HNSCC	80%
Reddy et al^Citation48 (2007)	II	India	17	III or IVA, HNSCC	76%			90% increase ORR
Brade (2007)	I	Canada	16	Advanced refractory CRC		43.8%
Crombet et al^Citation66 (2006)	II	Cuba	29	Gliomas	37.9%
Crombet (2008)	II/III	Cuba	65	GB, AA		68.6%		37.2% increase DCR
Bode (2007)	II	Germany	46	Pediatric brain cancer	30.4%	45.5%	10	150% increase MST
Bode (2008)	III	Germany	42	Pediatric brain cancer
Shah et al^Citation76 (2009)	II	Canada	61	Refractory CRC		50%	9.3
Reddy et al (2007)	II	India	20	III or IVA HNSCC	100%			42.9% increase in ORR

Notes: ORR = complete responses + partial responses. DCR = ORR + stable disease. vs controls are comparisons of nimotuzumab to non-nimotuzumab controls.

Abbreviations: NSCLC, non-small cell lung cancer; ORR, objective response rate; DCR, disease control rate; MST, median survival time; HNSCC, head and neck squamous cell carcinomas; CRC, colorectal cancer.

Table 2 Nimotuzumab trials in NSCLC

Authors	Phase	Location	No. of patients	Cancer	Dosage	ORR	DCR	MTP	OST
Bebb et al^Citation55	I	Canada	18	NSCLC	7@100 mg; 6@200 mg; 5@400 mg	66%a	94%a	5.4 mob	9.8 moc
Choi et al^Citation56	I	Korea	15	NSCLC	5@100 mg; 5@200 mg; 5@400 mg	46.7%a	100%a	164 dd	298 de
Macias et al^Citation58f	II	Cuba	21	NSCLC brain metastases	200 mg		91.6%

a Notes: ORR and DCR within radiation field;

b 95% CI, 0.9–9.9 months;

c 95% CI, 6.5–13.1 months;

d 95% CI, 26–302 days;

e 95% CI, 199–397 days;

f Based on preliminary results.

Abbreviations: NSCLC, non-small cell lung cancer; ORR, objective response rate; DCR, disease control rate; MST, median survival time; OST, overall survival time; CI, confidence interval.

CrombetTTorresLNeningerECatalaMSolanoMEPereraAPharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancerJ Immunother200326213914812616105

 PubMed Web of Science ®Google Scholar

WinquistENabidASicheriDA phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy (RT)Proc Am Soc Clin Oncol200221 Abstract 926

 Google Scholar

CrombetTOsorioMCruzTUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patientsJ Clin Oncol20042291646165415117987

 PubMed Web of Science ®Google Scholar

RojoFGraciasEVillenaNPharmacodynamic study of nimotuzumab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN): a SENDO Foundation studyJ Clin Oncol200826 Abstract 607018165637

 PubMed Web of Science ®Google Scholar

ReddyBKVidyasagarMShenoyKNimotuzumab (h-R3) in combination with chemoradiotherapy and radiotherapy in the treatment of squamous cell carcinoma of head and neck (SCCHN) Available from: http://astro2007.abstractsnet.com/handouts/500467_Biocon_h-R3.pdf2007

 Google Scholar

CrombetTFigueredoJCatalaMTreatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trialCancer Biol Ther20065437537916575203

 PubMed Web of Science ®Google Scholar

ShahAMChenEJonkerDA Phase II clinical trial of nimotuzumab, an EGFR monoclonal antibody (MAb), in metastatic colorectal cancer (mCRC)J Clin Oncol2009 In: Proceedings of ASCO GI symposium; 2009; Alexandria, VA. Abstract 358

 Google Scholar

BebbGSmithCRorkeSPhase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapyCancer Chemother Pharmacol2010620 [Epub ahead of print]

 Web of Science ®Google Scholar

ChoiHJSohnJHLeeCGA phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean resultsLung Cancer201055 [Epub ahead of print]

 Web of Science ®Google Scholar

MaciasANeningerESantiestebanEPreliminary results of a phase II clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer (NSCLC) and unresectable brain metastasesPaper presented at: EORTC-NCI-AACR Annual Meeting2008Geneva, Switzerland

 Google Scholar